KZIA Quote, Financials, Valuation and Earnings

Immutep has a net margin of -- compared to Kazia Therapeutics's net margin of --. Kazia Therapeutics's return on equity of -1083.16% beat Immutep's return on equity of --.

Kazia Therapeutics has a consensus price target of $2.98, signalling upside risk potential of 360.81%. On the other hand Immutep has an analysts' consensus of $9.50 which suggests that it could grow by 410.75%. Given that Immutep has higher upside potential than Kazia Therapeutics, analysts believe Immutep is more attractive than Kazia Therapeutics.

Kazia Therapeutics has a beta of 2.495, which suggesting that the stock is 149.537% more volatile than S&P 500. In comparison Immutep has a beta of 1.803, suggesting its more volatile than the S&P 500 by 80.329%.

Kazia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immutep offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kazia Therapeutics pays -- of its earnings as a dividend. Immutep pays out -- of its earnings as a dividend.

Kazia Therapeutics quarterly revenues are --, which are smaller than Immutep quarterly revenues of --. Kazia Therapeutics's net income of -- is lower than Immutep's net income of --. Notably, Kazia Therapeutics's price-to-earnings ratio is -- while Immutep's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kazia Therapeutics is 0.01x versus -- for Immutep. Usually stocks with elevated PS ratios are considered overvalued.

Immuron has a net margin of -- compared to Kazia Therapeutics's net margin of --. Kazia Therapeutics's return on equity of -1083.16% beat Immuron's return on equity of -53.91%.

Kazia Therapeutics has a consensus price target of $2.98, signalling upside risk potential of 360.81%. On the other hand Immuron has an analysts' consensus of -- which suggests that it could grow by 156.44%. Given that Kazia Therapeutics has higher upside potential than Immuron, analysts believe Kazia Therapeutics is more attractive than Immuron.

Kazia Therapeutics has a beta of 2.495, which suggesting that the stock is 149.537% more volatile than S&P 500. In comparison Immuron has a beta of 0.951, suggesting its less volatile than the S&P 500 by 4.931%.

Kazia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kazia Therapeutics pays -- of its earnings as a dividend. Immuron pays out -- of its earnings as a dividend.

Kazia Therapeutics quarterly revenues are --, which are smaller than Immuron quarterly revenues of --. Kazia Therapeutics's net income of -- is lower than Immuron's net income of --. Notably, Kazia Therapeutics's price-to-earnings ratio is -- while Immuron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kazia Therapeutics is 0.01x versus 2.60x for Immuron. Usually stocks with elevated PS ratios are considered overvalued.

Mesoblast has a net margin of -- compared to Kazia Therapeutics's net margin of --. Kazia Therapeutics's return on equity of -1083.16% beat Mesoblast's return on equity of --.

Kazia Therapeutics has a consensus price target of $2.98, signalling upside risk potential of 360.81%. On the other hand Mesoblast has an analysts' consensus of $27.00 which suggests that it could grow by 136.64%. Given that Kazia Therapeutics has higher upside potential than Mesoblast, analysts believe Kazia Therapeutics is more attractive than Mesoblast.

Kazia Therapeutics has a beta of 2.495, which suggesting that the stock is 149.537% more volatile than S&P 500. In comparison Mesoblast has a beta of 2.500, suggesting its more volatile than the S&P 500 by 150.01%.

Kazia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mesoblast offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kazia Therapeutics pays -- of its earnings as a dividend. Mesoblast pays out -- of its earnings as a dividend.

Kazia Therapeutics quarterly revenues are --, which are smaller than Mesoblast quarterly revenues of --. Kazia Therapeutics's net income of -- is lower than Mesoblast's net income of --. Notably, Kazia Therapeutics's price-to-earnings ratio is -- while Mesoblast's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kazia Therapeutics is 0.01x versus 118.31x for Mesoblast. Usually stocks with elevated PS ratios are considered overvalued.

Opthea has a net margin of -- compared to Kazia Therapeutics's net margin of --. Kazia Therapeutics's return on equity of -1083.16% beat Opthea's return on equity of --.

Kazia Therapeutics has a consensus price target of $2.98, signalling upside risk potential of 360.81%. On the other hand Opthea has an analysts' consensus of $1.33 which suggests that it could fall by -60.9%. Given that Kazia Therapeutics has higher upside potential than Opthea, analysts believe Kazia Therapeutics is more attractive than Opthea.

Kazia Therapeutics has a beta of 2.495, which suggesting that the stock is 149.537% more volatile than S&P 500. In comparison Opthea has a beta of 1.011, suggesting its more volatile than the S&P 500 by 1.132%.

Kazia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Opthea offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kazia Therapeutics pays -- of its earnings as a dividend. Opthea pays out -- of its earnings as a dividend.

Kazia Therapeutics quarterly revenues are --, which are smaller than Opthea quarterly revenues of --. Kazia Therapeutics's net income of -- is lower than Opthea's net income of --. Notably, Kazia Therapeutics's price-to-earnings ratio is -- while Opthea's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kazia Therapeutics is 0.01x versus 2,182.10x for Opthea. Usually stocks with elevated PS ratios are considered overvalued.